<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898673</url>
  </required_header>
  <id_info>
    <org_study_id>CLTD5804</org_study_id>
    <nct_id>NCT04898673</nct_id>
  </id_info>
  <brief_title>CP1110 Sound Processor Feasibility</brief_title>
  <official_title>A Pre-Marketing, Prospective, Multi-Site, Open-Label, Within-Subject, Feasibility, Interventional Study of Speech Perception With Experienced Adult Cochlear Implant Recipients Using the CP1110 Sound Processor and Compared With the CP1000 Sound Processor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cochlear</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cochlear</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study aims to investigate the speech performance with the CP1110 Sound&#xD;
      Processor, compared with the CP1000 Sound Processor, and inclusion of a noise reduction&#xD;
      feature in the Automatic Scene Classifier..&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will build on the evidence previously collected on behind-the-ear sound processors&#xD;
      and noise reduction, with particular focus on the speech perception performance of the CP1110&#xD;
      Sound Processor when compared to the CP1000 Sound Processor.&#xD;
&#xD;
      To assess the primary and secondary speech perception objectives, the study incorporates a&#xD;
      within-subject repeated-measures design in which each subject will undergo in-booth speech&#xD;
      perception testing with all combinations of hardware and signal processing settings in a&#xD;
      sound booth. The average difference scores will indicate the performance difference for each&#xD;
      of the paired comparisons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, pre-market, Multi-site, non-randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy measure for the CP1110 Sound Processor will be Speech Reception Thresholds (SRT) assessed via sentence scores in spatially separated adaptive noise</measure>
    <time_frame>One day</time_frame>
    <description>Paired difference in dB SRT between treatment and control, with their applicable noise reduction feature enabled.&#xD;
The speech recognition threshold (SRT) examines at which level the participant can repeat 50% of the speech material correctly. These scores may be negative or positive numeric values. Lower dB SRT scores indicate a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy measures will be the percentage words correct as assessed by CNC (Consonant Nucleus Consonant) Monosyllabic word scores in quiet.</measure>
    <time_frame>One day</time_frame>
    <description>Paired differences in percentage CNC Words correct in quiet (50 dB) between treatment and control, with various configurations of signal processing settings being enabled or disabled for each measure.&#xD;
Word recognition is a score of the number of words correctly repeated, expressed as a percentage. Higher percentage scores indicate a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adult Cochlear Implant Recipients</condition>
  <arm_group>
    <arm_group_label>CP1110 Sound Processor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP1000 Sound Processor.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CP1110</intervention_name>
    <description>Sound Processor</description>
    <arm_group_label>CP1110 Sound Processor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CP1000</intervention_name>
    <description>Sound Processor</description>
    <arm_group_label>CP1000 Sound Processor.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years or older&#xD;
&#xD;
          2. Post lingually deafened&#xD;
&#xD;
          3. Implanted with the CI600 Series (CI612, CI632, CI622, CI624), CI500 Series (CI512,&#xD;
             CI532, CI522) or Freedom Series (CI24RE(CA), CI24RE(ST), CI422)&#xD;
&#xD;
          4. At least 6 months experience with a cochlear implant.&#xD;
&#xD;
          5. At least 3 months experience with a Nucleus 6 (CP910/920), Kanso (CP950), Kanso 2&#xD;
             (CP1150) or Nucleus 7 (CP1000) Sound Processor&#xD;
&#xD;
          6. Able to score 30% or more at +15 SNR with CI alone on a sentence in babble test&#xD;
&#xD;
          7. Willingness to participate in and to comply with all requirements of the protocol.&#xD;
&#xD;
          8. Fluent speaker in English as determined by the investigator&#xD;
&#xD;
          9. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Additional disabilities that would prevent participation in evaluations.&#xD;
&#xD;
          2. Unrealistic expectations on the part of the subject, regarding the possible benefits,&#xD;
             risks and limitations that are inherent to the procedures.&#xD;
&#xD;
          3. Unable or unwilling to comply with the requirements of the clinical investigation as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          4. Investigator site personnel directly affiliated with this study and/or their immediate&#xD;
             families; immediate family is defined as a spouse, parent, child, or sibling.&#xD;
&#xD;
          5. Cochlear employees or employees of Contract Research Organisations or contractors&#xD;
             engaged by Cochlear for the purposes of this investigation.&#xD;
&#xD;
          6. Currently participating, or participated in another interventional clinical&#xD;
             study/trial in the past 30 days, or (if less than 30 days) the prior investigation was&#xD;
             Cochlear sponsored and determined by the investigator to not impact clinical findings&#xD;
             of this investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernadette Pickering</last_name>
    <phone>+61296115909</phone>
    <phone_ext>5909</phone_ext>
    <email>bpickering@cochlear.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Warren</last_name>
    <phone>+61296115938</phone>
    <phone_ext>5938</phone_ext>
    <email>cwarren@cochlear.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochlear Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esti Nel</last_name>
      <phone>+612 9428 6285</phone>
      <email>enel@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>Esti Nel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cochlear Melbourne</name>
      <address>
        <city>Melbourne E.</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Kerrie Plant</last_name>
      <phone>+61386623103</phone>
      <email>kplant@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>Dr Kerrie Plant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cochlear Technology Centre</name>
      <address>
        <city>Mechelen</city>
        <state>Antwerp</state>
        <zip>B-2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anke Plasmans</last_name>
      <phone>+3215795515</phone>
      <email>aplasmans@cochlear.com</email>
    </contact>
    <investigator>
      <last_name>Anke Plasmans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

